GSK-3 inhibition by adenoviral FRAT1 overexpression is neuroprotective and induces Tau dephosphorylation and beta-catenin stabilisation without elevation of glycogen synthase activity.
about
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNSGSK-3β: A Bifunctional Role in Cell Death PathwaysThe low density lipoprotein receptor-related protein 6 interacts with glycogen synthase kinase 3 and attenuates activityRegulation of Cullin-RING ubiquitin ligase 1 by Spliceosome-associated protein 130 (SAP130)Regulation of cullin RING E3 ubiquitin ligases by CAND1 in vivoCurrent Understanding on EGFR and Wnt/β-Catenin Signaling in Glioma and Their Possible CrosstalkSuppression of androgen receptor-mediated transactivation and cell growth by the glycogen synthase kinase 3 beta in prostate cellsFRAT-2 preferentially increases glycogen synthase kinase 3 beta-mediated phosphorylation of primed sites, which results in enhanced tau phosphorylationSubstrate-mediated regulation of cullin neddylationUncovering molecular biomarkers that correlate cognitive decline with the changes of hippocampus' gene expression profiles in Alzheimer's disease.Expression and characterization of GSK-3 mutants and their effect on beta-catenin phosphorylation in intact cells.Inhibition of hypoxia-inducible factor-1alpha (HIF-1alpha) protein synthesis by DNA damage inducing agentsMechanism of cullin3 E3 ubiquitin ligase dimerization.WNT10B mutations in human obesity.FRAT1, a substrate-specific regulator of glycogen synthase kinase-3 activity, is a cellular substrate of protein kinase A.Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation.Inhibition of adipocytogenesis by canonical WNT signaling in human mesenchymal stem cellsThe paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways.Characterization of the role of COP9 signalosome in regulating cullin E3 ubiquitin ligase activityLithium blocks the c-Jun stress response and protects neurons via its action on glycogen synthase kinase 3.Protein Profile and Morphological Alterations in Penumbra after Focal Photothrombotic Infarction in the Rat Cerebral Cortex.Reproductive Stage and Modulation of Stress-Induced Tau Phosphorylation in Female Rats.Characterization of the interaction between latency-associated nuclear antigen and glycogen synthase kinase 3beta.The marine natural-derived inhibitors of glycogen synthase kinase-3beta phenylmethylene hydantoins: In vitro and in vivo activities and pharmacophore modeling.Increased concentrations of fructose 2,6-bisphosphate contribute to the Warburg effect in phosphatase and tensin homolog (PTEN)-deficient cells.GSK-3β protein phosphorylates and stabilizes HLXB9 protein in insulinoma cells to form a targetable mechanism of controlling insulinoma cell proliferation.The role of selective transport in neuronal polarization.Nucleosomes structure and dynamics: effect of CHAPS.Pharmacophore-based screening and drug repurposing exemplified on glycogen synthase kinase-3 inhibitors.Overexpression of Frat1 correlates with malignant phenotype and advanced stage in human non-small cell lung cancer.Signalling activity of beta-catenin targeted to different subcellular compartments.In vivo regulation of glycogen synthase kinase 3β activity in neurons and brainsThe Wnt antagonist Dickkopf-1 and its receptors are coordinately regulated during early human adipogenesis.Downregulation of Mcl-1 through GSK-3β activation contributes to arsenic trioxide-induced apoptosis in acute myeloid leukemia cells.Anti-inflammatory activity of Wnt signaling in enteric nervous system: in vitro preliminary evidences in rat primary culturesPhosphorylation of PPP(S/T)P motif of the free LRP6 intracellular domain is not required to activate the Wnt/beta-catenin pathway and attenuate GSK3beta activity.Central role of glycogen synthase kinase-3beta in endoplasmic reticulum stress-induced caspase-3 activation.GSK-3β Inhibition Induced Neuroprotection, Regeneration, and Functional Recovery After Intracerebral Hemorrhagic Stroke.Endogenous IGF-I protects human intestinal smooth muscle cells from apoptosis by regulation of GSK-3 beta activity.Differential effects of glycogen synthase kinase 3 (GSK3) inhibition by lithium or selective inhibitors in the central nervous system.
P2860
Q21129334-DFF8F23D-E886-4332-A542-88DCBD29245BQ21285144-4D00A541-0A76-4E79-82E5-9EC3CB9918B0Q24299312-8E290E54-6D3D-46C5-A145-36DEC9FEC866Q24317967-BFE263E2-B691-4B89-A071-C3ECF3FEFFCFQ24337729-A6A13C02-280B-4B08-BF51-5E6C28B61139Q26865911-1DECF7C8-2E92-4E85-ACB6-4805C3A7A522Q28265036-F6299B70-FD08-4F09-8963-2AF799BD7F77Q28291371-6AE0E5A4-A7BC-451F-8A08-1E8EFAB2EBB5Q28298285-64466C8F-4716-4CC6-A8D6-E751BC3CC0BDQ30494084-3BA02E7C-BF59-4EA6-A143-3A2E361B7D9CQ33183622-C681881A-FCCD-43B9-AAA7-AC3A614458AFQ33580209-B275013E-DA56-4423-B84D-8F16B2FBA3FAQ34387857-3C077157-9891-4AF4-9068-33B0E832071EQ34494404-15D5CB80-DC54-4A7D-98ED-B71F49987A72Q34566865-D936C9CC-9EFF-4799-9C51-D3C2474EF1C2Q34732988-DD87A5AD-CD28-4677-BA3D-D45BA44FCE4BQ35090349-05CDD55F-392E-4922-8E34-801EBDA5FED3Q35103813-B5A94053-D88A-44D5-8C50-32C384ADEBCFQ35612223-E62C2EF8-27A4-44CB-BCE4-7373BAE7C8CEQ35661658-7AC77EE7-1C07-41BE-84D0-319AFBD30CC5Q36057317-263D6CD1-B888-4314-883D-338AAC777569Q36222556-F3C7A2D3-C315-48A7-B552-517B0DAED8DFQ37204595-5A4582E4-409D-40BA-A9D6-C2334E420737Q37345648-346AC4D7-3591-45EC-BD48-8863B9FF14C6Q37388842-DF50EE4E-1076-4EEC-9E53-F30E587DCF7DQ37608407-E984022A-5C0D-4B58-A26E-19AF56EC48D5Q37838910-2FF0F824-2743-4B17-B37E-6F832C55141CQ38561833-ABCA3755-96F0-4C8C-84E3-8AA858D1B547Q39008696-100E3360-C756-4867-AB4F-862A32E33827Q39494690-326EEA1A-0C95-499A-8FC9-9B732D6D07E5Q40597673-E3C9D70A-37B4-478B-8543-3E60E208F8E7Q41447595-A813C61C-6B70-485E-8710-8FB7D36F5F1BQ41846475-CFAEA470-1CF0-491F-A02E-537445B6963BQ41878659-9ABDB441-511A-450F-A208-8D9D002DB110Q42119593-71CDF839-A3FB-4AA4-8223-32D31D546EF3Q42722184-495C391C-3479-4E28-9626-76FFCA691664Q44135113-D44483C1-698D-498B-808B-3A0C0A858E9CQ44627005-CBFDED15-7A2E-4011-8CCE-68FE657B7D5CQ44904081-BD69FA84-F492-46FC-A4BC-0F2AF81F5854Q50884859-B63FC019-805E-4B7F-8172-3FE87C094B17
P2860
GSK-3 inhibition by adenoviral FRAT1 overexpression is neuroprotective and induces Tau dephosphorylation and beta-catenin stabilisation without elevation of glycogen synthase activity.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
GSK-3 inhibition by adenoviral ...... of glycogen synthase activity.
@en
GSK-3 inhibition by adenoviral ...... of glycogen synthase activity.
@nl
type
label
GSK-3 inhibition by adenoviral ...... of glycogen synthase activity.
@en
GSK-3 inhibition by adenoviral ...... of glycogen synthase activity.
@nl
prefLabel
GSK-3 inhibition by adenoviral ...... of glycogen synthase activity.
@en
GSK-3 inhibition by adenoviral ...... of glycogen synthase activity.
@nl
P2093
P2860
P921
P1433
P1476
GSK-3 inhibition by adenoviral ...... of glycogen synthase activity.
@en
P2093
Culbert AA
P2860
P304
P356
10.1016/S0014-5793(01)02990-8
P407
P577
2001-11-01T00:00:00Z